Investigating the effects of IL-5 on asthma and immune responses
Non-Eosinophilic Biological Effects of Interleukin 5 (IL-5) - Role of IL-5 in Suppressing Anti-Viral Immunity in Bronchial Epithelial Cells and Dendritic Cells in Asthma
This study is trying to see how a substance called IL-5 affects asthma and the immune system in people with asthma, especially during viral infections, and whether treatments that lower IL-5 can help improve their immune response.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Imperial College London Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT06026202 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of interleukin 5 (IL-5) in modulating immune responses in individuals with asthma. It focuses on how IL-5 may suppress anti-viral immunity in bronchial epithelial cells and peripheral blood mononuclear cells, particularly during viral infections. The study will assess whether elevated IL-5 levels correlate with reduced interferon production, which is known to help mitigate asthma exacerbations. Additionally, the research will evaluate the impact of anti-IL-5 therapies on IL-5 levels and their potential to restore anti-viral immunity in asthma patients.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with stable eosinophilic asthma who are eligible for the MAELABA study.
Not a fit: Patients with non-eosinophilic asthma or those not eligible for the MAELABA study may not benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of asthma exacerbations related to viral infections.
How similar studies have performed: While the specific approach of this study is novel, existing research has indicated the importance of IL-5 in asthma, suggesting potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Must be eligible for the study 'Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma' (MAELABA) (19SM5101).
Where this trial is running
London
- Imperial College London — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Sebastian L Johnston, MBBS
- Email: s.johnston@imperial.ac.uk
- Phone: +44 20 7594 3764
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.